TrialJournal of the American Academy of Dermatology2021

Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.

Brett King et al.PubMed ↗Publisher ↗

No numbers read from the abstract.